Hepatotoxicity of metronidazole in Cockayne syndrome: A clinical report.
Fiche publication
Date publication
novembre 2021
Journal
European journal of medical genetics
Auteurs
Membres identifiés du Cancéropôle Est :
Pr THIEFIN Gérard, Dr BOULAGNON-ROMBI Camille
Tous les auteurs :
Hunaut T, Boulagnon-Rombi C, Thorn H, Doco-Fenzy M, Thiéfin G
Lien Pubmed
Résumé
Cockayne syndrome (CS) is a rare autosomal recessive genetic disorder characterized by growth failure and progressive multisystem dysfunction caused by deficient nucleotide excision repair. Whereas metronidazole (MTZ) hepatotoxicity is quite rare in the general population, cases of severe hepatic reaction to MTZ have been reported in CS patients. We report here the case of a 21-year-old CS patient who presented with jaundice following one week of treatment with MTZ combined with spiramycin for dental care. This case is the first one documented with a liver biopsy. Histopathological analysis revealed portal and lobular inflammation with predominance of neutrophils, ballooning degeneration and severe cholestasis without bile duct damage. The outcome was marked by regression of jaundice over 6 weeks. Analysis of this case highlights the probable responsibility of MTZ and adds support to the recommendation to strictly avoid the prescription of this drug in CS patients.
Mots clés
Cockayne syndrome, Hepatotoxicity, Metronidazole, Spiramycin
Référence
Eur J Med Genet. 2021 Nov 9;:104388